Review of clinical trials of the IL-23 inhibitor guselkumab. Experience of using genetically engineered biological therapy with guselkumab in a patient with severe arthropathic psoriasis


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

This article discusses the modern pathogenetic mechanisms of the development of psoriasis, new drugs, the action of which is aimed at different links of pathogenesis. Particular attention is paid to clinical studies on the efficacy and safety of the interleukin-23 inhibitor guselkumab. A clinical case of a patient with widespread psoriasis vulgaris with joint damage is presented. Patient was under medical supervision and received therapy with guselkumab for 3 months. The analysis of the treatment results was carried out. The data obtained indicate an improvement in the indicators of the quality of life and working capacity. Convenient dosage regimen and low immunogenicity of this drug can significantly increase the effectiveness and tolerability of the therapy.

全文:

受限制的访问

作者简介

Elena Svechnikova

Polyclinic № 1 of the Administrative Department of the President of the Russian Federation ; Novosibirsk State Medical University

Email: elene-elene@bk.ru
Dr. Sci. (Med.), Head of the Department of Dermatovenereology and Cosmetology, Polyclinic № 1 of the Administrative Department of the President of the Russian Federation ; Professor at the Department of Dermatovenereology and Cosmetology, Novosibirsk State Medical University

参考

  1. Tang, L., Yang X., Liang Y., et al. Transcription Factor Retinoid-Related Orphan Receptor yt: A Promising Target for the Treatment of Psoriasis. Front Immunol. 2018;9:1210. Doi: 10.3389/ fimmu.2018.01210.
  2. Tokuyama M., Mabuchi T. New Treatment Addressing the Pathogenesis of Psoriasis. J Mol Sci. 2020;21:7488. Doi: 10.3390/ ijms21207488.
  3. Light J.G., Su J.J., Feldman S.R. Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis. Clin Cosmet Invest Dermatol. 2021;14:55-63. Doi: 10.2147/ CCID.S235242.
  4. Знаменская Л.Ф., Чикин В.В., Бакулев А.Л. и др. Федеральные клинические рекомендации по ведению больных псориазом. М., 2015
  5. Pandya V.B., Kumar S., Sachchidanand, et al. Combating Autoimmune Diseases with Retinoic Acid Receptor-Related Orphan Receptor-Y (RORY or RORc) Inhibitors: Hits and Misses. J Med Chem. 2018;61:10976-995. Doi: 10.1021/ acs.jmedchem.8b00588.
  6. Bachelez H., Choon S., Marrakchi S., et al. Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis. N Engl J Med. 2019;380:981-83. Doi: 10.1056/ NEJMc1811317.
  7. Bell M., Foley D., Naylor C., et al. Discovery of Super Soft-Drug Modulators of Sphingosine-1-Phosphate Receptor 1. Bioorg Med Chem. 2018;28:3255-59. Doi: 10.1016/j. bmcl.2018.07.044.
  8. Zanin-Zhorov A., Weiss J.M., Trzeciak A.J., et al. Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. J Immunol. 2017;198:3809-14.
  9. Лыткина К.А., Зянгиров Р.Р. Безопасность биологических препаратов у пациентов с псориазом и псориатическим артритом: анализ данных регистров пациентов. Русский медицинский журнал. 2016;22:1511-16
  10. Deodhar A., Helliwell P.S., Boehncke W.-H., et. al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFa inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020. doi: 10.1016/S0140-6736(20)30265-8.
  11. Blauvelt A., Papp K.A., Griffiths C.E.M. Efficacy and safety of guselkumab, an antiinterleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatorecontrolled Voyage 1 trial. J Am Acad Dermatol. 2017. Doi: https://doi.org/10.1016/j.jaad.2016.11.041
  12. Reich K., Griffiths C.E.M., et.al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936-45. Doi: 10.1016/j. jaad.2019.11.040.
  13. Reich K., Armstrong A.W. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418-31. Doi: 10.1016/j. jaad.2016.11.042.
  14. Langley R.G. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2017;178(1):114-23. doi: 10.1111/bjd.15750.
  15. Reich K., Armstrong A.W., Langley R.G., et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831-doi: 10.1016/s0140-6736(19)31773-8.
  16. Ferris L.K., Ott E., Jiang J., et al. Efficacy and safety of guselkumab, administered with a novel patientcontrolled injector (one-press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. J Dermatol Treat. 2019;31(2): 152-59. doi: 10.1080/09546634. 2019.1587145.
  17. Blauvelt A., Papp K., Gottlieb A., et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, doubleblinded trial. Br J Dermatol. 2020;182(6):1348-58. doi: 10.1111/bjd.18851.
  18. Thaci D., Pinter A., Sebastian M., et al. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). Br J Dermatol. 2020;183(2):265-75. doi: 10.1111/bjd.18696.
  19. Yamamoto Т., Fukuda К., Morita А., et al. Efficacy of guselkumab in a subpopulation with pustulotic arthroosteitis through week 52: an exploratory analysis of a phase 3, randomized, doubleblind, placebo-controlled study in Japanese patients with palmoplantar pustulosis. J Eur Acad Dermatol Venereol. 2020;34(10):2318-29. doi: 10.1111/jdv.16355.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2021